Miryalaguda

A company executive said on Tuesday that the US drug regulator's observations on its active pharmaceutical ingredient plant at Miryalaguda are minor and easily addressable.

Dr Reddy's receives 3 USFDA observations for Miryalaguda plant

The company didn‘t explain the nature of these observations. Miryalaguda plant was one among the three plants for which the company got US drug regulator warning letter in November 2015.

Dr Reddy's Miryalaguda facility gets 3 USFDA observations

Drug firm Dr Reddy's Laboratories today said the US health regulator has made three observations after completing inspection of its Miryalaguda facility.

USFDA warning: Have 15 days to respond, says DRL CFO

Saumen Chakraborty, CFO, Dr Reddy's Laboratories, says "The warning letter has come telling the management to respond within 15 working days in terms of strategy and plan."

Dr Reddy's gets FDA warning letter for three drug plants

The warning letter was issued by the FDA to Dr Reddy's on Thursday for its Srikakulam, Miryalaguda and Duvvada drug manufacturing plants - all based in southern India.

Dr Reddy's tanks 15% post warning letter from USFDA

The warning letter is relating to its API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as Oncology Formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh.